Adeptus Health Inc Stock News

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the upcoming 42 nd Annual Cowen Healthcare Conference.

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ge

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sy

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17 th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associated with CD utilizing Adaptive’s immunoSEQ ® technology, providing fundamental insights into the body’s response to CD at the cellular level.

Data being presented at the 17 th European Crohn''s and Colitis Organisation (ECCO) exhibit the use of Adaptive''s ImmunoSEQ ® technology to successfully identify T-cell receptors (TCR) associated with Crohn''s disease using blood samples Findings support the importance of identifying and analyzing T-cell receptors associated with Crohn''s disease, potentially opening a new path to diagnosis and providing further insights into disease subtypes SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT ), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn''s disease (CD) during an oral presentation today at the 17 th Congress of European Crohn''s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associated with CD utilizing Adaptive''s immunoSEQ ® technology, providing fundamental insights into the body''s response to CD at the cellular level.

Adaptive Biotechnologies Corp (NASDAQ: ADPT ) reported Q4 sales of $37.9 million, +26% Y/Y , beating the estimate of $36.37 million. "As we move into 2022, I am encouraged by the momentum and the multiple shots on goal across our businesses, which could positively … Full story available on Benzinga.com

ADPT earnings call for the period ending December 31, 2021.

ADPT earnings call for the period ending December 31, 2021.

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 5.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies press release (ADPT): Q4 GAAP EPS of -$0.43 beats by $0.02.Revenue of $37.9M (+25.5% Y/Y) beats by $1.05M.Shares -3.9%.

SEATTLE, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the g

SEATTLE, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Adaptive Biotechnologies Corp (ADPT) CEO Chad Robins on Q4 2021 Results - Earnings Call Transcript